Zobrazeno 1 - 10
of 393
pro vyhledávání: '"Sercan Aksoy"'
Autor:
Byoung Chul Cho, Irene Braña, Beatriz Cirauqui, Sercan Aksoy, Felix Couture, Ruey-Long Hong, Wilson H. Miller, Manuel Chaves-Conde, Margarida Teixeira, Lance Leopold, Mihaela Munteanu, Joy Yang Ge, Ramona F. Swaby, Brett G. M. Hughes
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-12 (2024)
Abstract Background Advanced head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, and new treatment options are needed. Combining immunotherapies with differing mechanisms of action may enhance clinical benefits compared with single-ag
Externí odkaz:
https://doaj.org/article/24bfd93adc7946a58a1c047c4d340cb7
Autor:
Ozge Saatci, Rashedul Alam, Kim-Tuyen Huynh-Dam, Aynur Isik, Meral Uner, Nevin Belder, Pelin Gulizar Ersan, Unal Metin Tokat, Burge Ulukan, Metin Cetin, Kubra Calisir, Mustafa Emre Gedik, Hilal Bal, Ozlem Sener Sahin, Yasser Riazalhosseini, Denis Thieffry, Daniel Gautheret, Besim Ogretmen, Sercan Aksoy, Aysegul Uner, Aytekin Akyol, Ozgur Sahin
Publikováno v:
Cell Death and Disease, Vol 15, Iss 6, Pp 1-14 (2024)
Abstract Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER + ) breast cancer, constituting around 75% of all cases. However, the emergence of resistance is common, necessitating th
Externí odkaz:
https://doaj.org/article/736322c0c13e4be88e8c36818fc7c5ab
Autor:
Ozge Saatci, Metin Cetin, Meral Uner, Unal Metin Tokat, Ioulia Chatzistamou, Pelin Gulizar Ersan, Elodie Montaudon, Aytekin Akyol, Sercan Aksoy, Aysegul Uner, Elisabetta Marangoni, Mathew Sajish, Ozgur Sahin
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract Resistance to endocrine therapy and CDK4/6 inhibitors, the standard of care (SOC) in estrogen receptor-positive (ER+) breast cancer, greatly reduces patient survival. Therefore, elucidating the mechanisms of sensitivity and resistance to SOC
Externí odkaz:
https://doaj.org/article/12ad9995bcd94038ac3e1cc764cb8625
Autor:
Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 170-176 (2023)
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers to identify patients who may
Externí odkaz:
https://doaj.org/article/67323cc7fe9e425d97196951b9a3b644
Autor:
Burak Yasin Aktaş, Emine Büşra Ata, Engin Çeşmeci, İbrahim Yahya Çakır, Muharrem Coşkunpınar, Yağmur Tahillioğlu, Gürkan Güner, Deniz Can Güven, Zafer Arık, Neyran Kertmen, Ömer Dizdar, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Current Oncology, Vol 30, Iss 11, Pp 9689-9700 (2023)
Anemia remains an essential concern affecting the quality of life and the survival of cancer patients. Although there are different approaches to treating anemia in cancer patients, the number of studies reporting the efficacy of iron replacement in
Externí odkaz:
https://doaj.org/article/f55f571aa8f04f59a35f393210fd57cc
Autor:
Taha Koray Sahin, Arif Akyildiz, Osman Talha Dogan, Gozde Kavgaci, Deniz Can Guven, Sercan Aksoy
Publikováno v:
Pharmaceuticals, Vol 17, Iss 7, p 824 (2024)
Trastuzumab emtansine (T-DM1) is a mainstay therapy for HER2-positive metastatic breast cancer (mBC). However, identifying patients who will benefit most remains a challenge due to the lack of reliable biomarkers. The recently developed pan-immune-in
Externí odkaz:
https://doaj.org/article/cba09664a7234950a7696ece067a4ea8
Publikováno v:
Cancers, Vol 16, Iss 10, p 1835 (2024)
Background: Cancer remains a leading cause of death globally, necessitating the identification of prognostic biomarkers to guide treatment decisions. The Royal Marsden Hospital (RMH) score, based on readily available blood tests and clinical features
Externí odkaz:
https://doaj.org/article/6a0e7682bb7e4566b558ee36b00c8c38
Autor:
Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci, Merve Keskinkılıç, Naziyet Köse Baytemür, Funda Yılmaz, Oğuzhan Selvi, Dilek Erdem, Esin Avşar, Nail Paksoy, Necla Demir, Sema Sezgin Göksu, Sema Türker, Ertuğrul Bayram, Abdüssamet Çelebi, Hatice Yılmaz, Ömer Faruk Kuzu, Seda Kahraman, İvo Gökmen, Abdullah Sakin, Ali Alkan, Erdinç Nayır, Muzaffer Uğraklı, Ömer Acar, İsmail Ertürk, Hacer Demir, Ferit Aslan, Özlem Sönmez, Taner Korkmaz, Özde Melisa Celayir, İbrahim Karadağ, Erkan Kayıkçıoğlu, Teoman Şakalar, İlker Nihat Öktem, Tülay Eren, Enes Erul, Eda Eylemer Mocan, Ziya Kalkan, Nilgün Yıldırım, Yakup Ergün, Baran Akagündüz, Serdar Karakaya, Engin Kut, Fatih Teker, Burçin Çakan Demirel, Kubilay Karaboyun, Elvina Almuradova, Olçun Ümit Ünal, Abdilkerim Oyman, Deniz Işık, Kerem Okutur, Buğra Öztosun, Burcu Belen Gülbağcı, Mehmet Emin Kalender, Elif Şahin, Mustafa Seyyar, Özlem Özdemir, Fatih Selçukbiricik, Metin Kanıtez, İsa Dede, Mahmut Gümüş, Erhan Gökmen, Arzu Yaren, Serkan Menekşe, Senar Ebinç, Sercan Aksoy, Gökşen İnanç İmamoğlu, Mustafa Altınbaş, Bülent Çetin, Başak Oyan Uluç, Özlem Er, Nuri Karadurmuş, Atike Pınar Erdoğan, Mehmet Artaç, Özgür Tanrıverdi, İrfan Çiçin, Mehmet Ali Nahit Şendur, Esin Oktay, İbrahim Vedat Bayoğlu, Semra Paydaş, Adnan Aydıner, Derya Kıvrak Salim, Çağlayan Geredeli, Tuğba Yavuzşen, Mutlu Doğan, İlhan Hacıbekiroğlu
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment
Externí odkaz:
https://doaj.org/article/042edc2981bf4d52a01526b7a7c03f4f
Autor:
Gürkan Güner, Levent Özçakar, Yusuf Baytar, Mehmet Ruhi Onur, Metin Demir, Burak Yasin Aktaş, Oktay Halit Aktepe, Deniz Can Güven, Hakan Taban, Hasan Çağrı Yıldırım, Serkan Akın, Sercan Aksoy, Murat Kara, Ömer Dizdar
Publikováno v:
Cancers, Vol 16, Iss 5, p 1061 (2024)
The objective of this study was to explore the possible association between low skeletal muscle mass (SMM)—assessed by computed tomography (CT) and ultrasound (US)—and hematologic toxicity in cancer patients. A prospective cohort study was conduc
Externí odkaz:
https://doaj.org/article/9af7844ab5994ce7894cd6bbdbe9fd61
Autor:
Hasan Çağrı Yıldırım, Emel Mutlu, Elvin Chalabiyev, Miraç Özen, Merve Keskinkılıç, Sercan Ön, Abdussamet Çelebi, Bengü Dursun, Ömer Acar, Seda Kahraman, Musa Barış Aykan, Ömür Kaman, Akif Doğan, Atike Pınar Erdoğan, Özde Melisa Celayir, Damla Günenç, Deniz Can Güven, İbrahim Vedat Bayoğlu, Tuğba Yavuzşen, İlhan Hacıbekiroğlu, Mevlüde İnanç, Saadettin Kılıçkap, Şuayib Yalçın, Sercan Aksoy
Publikováno v:
Breast, Vol 66, Iss , Pp 85-88 (2022)
Background: Since breast cancer is less common in men than in women, data on the use of new therapeutic agents, including cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors, are limited in patients with metastatic hormone receptor positive (HR+), h
Externí odkaz:
https://doaj.org/article/18da86563ce64050a659105850fa47be